Welcome!

News Feed Item

Bladder Cancer: So Much Cost, Such Little Progress

LONDON, March 20, 2014 /PRNewswire/ --



The alarming truth about the huge financial and personal impact of bladder cancer is highlighted in a new paper published in European  Urology[1]. The UK charity, Action on Bladder Cancer, co-authors an editorial[2] on the paper, drawing attention to the urgent need to address the enormous, yet largely ignored, burden that this distressing disease places on individuals and society.

     (Logo: http://photos.prnewswire.com/prnh/20130507/613105 )

Bladder cancer has the highest lifetime treatment costs per patient of all cancers[3]. The direct medical costs of cancer care in the UK are £65M[4]. As the seventh most common cancer in the UK, bladder cancer accounts for 1 in 30 new cases of cancer each year[5]. Even so, outcomes for bladder cancer have changed little for three decades, despite significant improvements in the 5-year survival rates for prostate and kidney cancers during this same period[2].

Bladder cancer has a deep and devastating reach into the health of our society. Overall, deaths from the disease remain higher in England than other European countries with similar incidence rates and survival is worsening[6].  On average 14 people die each day from bladder cancer[4], and yet it is largely neglected by those who could make a difference to the lives of so many people.

The paper and editorial discuss the key issues which are creating and sustaining this unacceptable situation:

  • There are large gaps in our knowledge regarding the efficacy and cost-effectiveness of treatment approaches
  • There is a lack of research funding compared to other cancers; despite being the seventh most common cancer, bladder cancer receives just 0.6% of NCRI cancer research spending in the UK[7]
  • There is a lack of sufficient randomized controlled trials (RCTs). RCTs provide the strongest evidence on which clinicians can base their practice however only 238 RCTs were published for bladder cancer between 1995 and 2010[8].
  • There is a clear and urgent need for the development of new drugs for bladder cancer.

As a result, bladder cancer still does not have a robust evidence base to support much of what is current everyday practice. Patient pathways of care are complex and prolonged, resulting in large variations in practice worldwide. Even at the basic level of public awareness of the disease, many people have not heard of bladder cancer and do not recognise that even just one episode of visible blood in the urine may indicate that bladder cancer may be present. For many people, diagnosis is delayed or misdiagnosed resulting in worse clinical outcomes. This is clearly just not good enough.

Mr Richard T Bryan, Chief Investigator, Bladder Cancer Prognosis Programme, and Senior Research Fellow, University of Birmingham, and Action on Bladder Cancer Regional Advisor says "The review by Svatek et al demonstrates the huge costs associated with the diagnosis and management of bladder cancer, the large variations in practice worldwide, and the significant gaps in our knowledge. Our accompanying editorial expands on these themes and others; most importantly, the lack of improvement in outcomes for bladder cancer patients over the last three decades, the poor funding for bladder cancer research, and the poor awareness of bladder cancer amongst the general public and the non-urologic scientific community. We need to advance the cause for bladder cancer patients and make much more progress with this very common disease."

Bladder cancer lags starkly behind nearly all other cancers. Action needs to be taken now to improve the life expectancy of so many people with bladder cancer. Quite simply, more has to be done.

About  Action  on  Bladder  Cancer 

Action on Bladder Cancer is a UK charity working to improve public awareness, medical knowledge and the priority of bladder cancer on the UK health agenda, to ensure earlier recognition and diagnosis and so allow more effective management to improve the outcomes for people with bladder cancer. (http://www.actiononbladdercancer.org).

References:

  1. Svatek et al. The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease. European Urology. Published online Feb 2014. Abstract available at: http://www.europeanurology.com/article/S0302-2838(14)00018-9/abstract/the-economics-of-bladder-cancer-costs-and-considerations-of-caring-for-this-disease
  2. Bryan RT et al. So much cost, such little progress. European Urology. Published online Feb 2014.  http://www.europeanurology.com/article/S0302-2838(14)00160-2/abstract
  3. Sievert KD et al. Economic aspects of bladder cancer. What are the benefits and costs? World  J  Urol. Jun 2009; 27(3): 295-300.
  4. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TR, N'Dow J, Nabi G, Cook J, Vale L. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess 2010; 14:1-iv
  5. Cancer Research UK, Cancer Stats Key Facts, Bladder Cancer http://www.cancerresearchuk.org/cancer-info/cancerstats/keyfacts/bladder-cancer/uk-bladder-cancer-statistics
  6. Eylert MF et al (2014). Falling bladder cancer incidence from 1990 to 2009 is not producing universal mortality improvements. Journal  of  Clinical  Urology 0(0) 1-9
  7. National Cancer Research Institute. NCRI spend by cancer site.  Available at http://www.ncri.org.uk/what-we-do/research-database
  8. Bachir, B. G., Shariat, S. F., Zlotta, A., Svatek, R., Black, P. C., Shah, J. B., Kassouf, W., Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada) (2013), Demographic analysis of randomized controlled trials in bladder cancer.  BJU  International, 111: 419-426


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Nihon Micron will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Nihon Micron Co., Ltd. strives for technological innovation to establish high-density, high-precision processing technology for providing printed circuit board and metal mount RFID tags used for communication devices. For more inf...
SYS-CON Events announced today that Massive Networks, that helps your business operate seamlessly with fast, reliable, and secure internet and network solutions, has been named "Exhibitor" of SYS-CON's 21st International Cloud Expo ®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. As a premier telecommunications provider, Massive Networks is headquartered out of Louisville, Colorado. With years of experience under their belt, their team of...
SYS-CON Events announced today that Suzuki Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Suzuki Inc. is a semiconductor-related business, including sales of consuming parts, parts repair, and maintenance for semiconductor manufacturing machines, etc. It is also a health care business providing experimental research for...
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
Many organizations adopt DevOps to reduce cycle times and deliver software faster; some take on DevOps to drive higher quality and better end-user experience; others look to DevOps for a clearer line-of-sight to customers to drive better business impacts. In truth, these three foundations go together. In this power panel at @DevOpsSummit 21st Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, industry experts will discuss how leading organizations build application success from all...
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
Cloud-based disaster recovery is critical to any production environment and is a high priority for many enterprise organizations today. Nearly 40% of organizations have had to execute their BCDR plan due to a service disruption in the past two years. Zerto on IBM Cloud offer VMware and Microsoft customers simple, automated recovery of on-premise VMware and Microsoft workloads to IBM Cloud data centers.
Why Federal cloud? What is in Federal Clouds and integrations? This session will identify the process and the FedRAMP initiative. But is it sufficient? What is the remedy for keeping abreast of cutting-edge technology? In his session at 21st Cloud Expo, Rasananda Behera will examine the proposed solutions: Private or public or hybrid cloud Responsible governing bodies How can we accomplish?
Today traditional IT approaches leverage well-architected compute/networking domains to control what applications can access what data, and how. DevOps includes rapid application development/deployment leveraging concepts like containerization, third-party sourced applications and databases. Such applications need access to production data for its test and iteration cycles. Data Security? That sounds like a roadblock to DevOps vs. protecting the crown jewels to those in IT.
SYS-CON Events announced today that Cedexis will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Cedexis is the leader in data-driven enterprise global traffic management. Whether optimizing traffic through datacenters, clouds, CDNs, or any combination, Cedexis solutions drive quality and cost-effectiveness.
Elon Musk is among the notable industry figures who worries about the power of AI to destroy rather than help society. Mark Zuckerberg, on the other hand, embraces all that is going on. AI is most powerful when deployed across the vast networks being built for Internets of Things in the manufacturing, transportation and logistics, retail, healthcare, government and other sectors. Is AI transforming IoT for the good or the bad? Do we need to worry about its potential destructive power? Or will we...
SYS-CON Events announced today that B2Cloud will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. B2Cloud specializes in IoT devices for preventive and predictive maintenance in any kind of equipment retrieving data like Energy consumption, working time, temperature, humidity, pressure, etc.
In his session at @ThingsExpo, Greg Gorman is the Director, IoT Developer Ecosystem, Watson IoT, will provide a short tutorial on Node-RED, a Node.js-based programming tool for wiring together hardware devices, APIs and online services in new and interesting ways. It provides a browser-based editor that makes it easy to wire together flows using a wide range of nodes in the palette that can be deployed to its runtime in a single-click. There is a large library of contributed nodes that help so...